Sung, H. et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209–249 (2021).

Article  PubMed  Google Scholar 

Yang, J. D. et al. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat. Rev. Gastroenterol. Hepatol. 16, 589–604 (2019).

Article  PubMed  PubMed Central  Google Scholar 

Rumgay, H. et al. Global burden of primary liver cancer in 2020 and predictions to 2040. J. Hepatol. 77, 1598–1606 (2022).

Article  PubMed  PubMed Central  Google Scholar 

International Agency for Research on Cancer. Cancer today. Global Cancer Observatory https://gco.iarc.who.int/today (2024).

Rumgay, H. et al. Global, regional and national burden of primary liver cancer by subtype. Eur. J. Cancer 161, 108–118 (2022).

Article  PubMed  Google Scholar 

Lee, Y. T. et al. Increasing incidence of intrahepatic cholangiocarcinoma relative to hepatocellular carcinoma in the United States. Gastro Hep Adv. 1, 121–124 (2022).

Article  PubMed  PubMed Central  Google Scholar 

GBD 2019 Hepatitis B Collaborators.Global, regional, and national burden of hepatitis B, 1990–2019: systematic analysis for the Global Burden of Disease Study 2019. Lancet Gastroenterol. Hepatol. 7, 796–829 (2022).

Article  Google Scholar 

Papatheodoridis, G. V. et al. Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B. J. Hepatol. 73, 1037–1045 (2020).

Article  CAS  PubMed  Google Scholar 

Yuan, B. H. et al. Lower risk of hepatocellular carcinoma with tenofovir than entecavir treatment in subsets of chronic hepatitis B patients: an updated meta-analysis. J. Gastroenterol. Hepatol. 37, 782–794 (2022).

Article  CAS  PubMed  Google Scholar 

Nahon, P. et al. Eradication of hepatitis C virus infection in patients with cirrhosis reduces risk of liver and non-liver complications. Gastroenterology 152, 142–156.e2 (2017).

Article  PubMed  Google Scholar 

Dang, H. et al. Cure with interferon-free direct-acting antiviral is associated with increased survival in patients with hepatitis C virus-related hepatocellular carcinoma from both East and West. Hepatology 71, 1910–1922 (2020).

Article  CAS  PubMed  Google Scholar 

Huang, D. Q., El-Serag, H. B. & Loomba, R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nat. Rev. Gastroenterol. Hepatol. 18, 223–238 (2021).

Article  PubMed  Google Scholar 

Huang, D. Q., Mathurin, P., Cortez-Pinto, H. & Loomba, R. Global epidemiology of alcohol-associated cirrhosis and HCC: trends, projections and risk factors. Nat. Rev. Gastroenterol. Hepatol. 20, 37–49 (2023).

Article  PubMed  Google Scholar 

Liu, Y. et al. Contribution of alcohol use to the global burden of cirrhosis and liver cancer from 1990 to 2019 and projections to 2044. Hepatol. Int. 17, 1028–1044 (2023).

Article  PubMed  Google Scholar 

Manthey, J. et al. Global alcohol exposure between 1990 and 2017 and forecasts until 2030: a modelling study. Lancet 393, 2493–2502 (2019).

Article  PubMed  Google Scholar 

Chan, W. K. et al. Metabolic dysfunction-associated steatotic liver disease (MASLD): a state-of-the-art review. J. Obes. Metab. Syndr. 32, 197–213 (2023).

Article  PubMed  PubMed Central  Google Scholar 

Yeo, Y. H., Zou, B., Cheung, R. & Nguyen, M. H. Increased mortality of patients with alcohol-related liver diseases during the COVID-19 pandemic in the United States. J. Intern. Med. 292, 837–839 (2022).

Article  CAS  PubMed  Google Scholar 

Mamudu, H. M. et al. The prevalence of metabolic conditions before and during the COVID-19 pandemic and its association with health and sociodemographic factors. PLoS ONE 18, e0279442 (2023).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sowah, L. & Chiou, C. Impact of coronavirus disease 2019 pandemic on viral hepatitis elimination: what is the price. AIDS Res. Hum. Retroviruses 37, 585–588 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kaur, S. P. et al. Hepatocellular carcinoma in hepatitis B virus-infected patients and the role of hepatitis B surface antigen (HBsAg). J. Clin. Med. 11, 1123 (2022).

Article  Google Scholar 

Wu, C. Y. et al. Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B: a nationwide cohort study. Gastroenterology 147, 143–151.e5 (2014).

Article  CAS  PubMed  Google Scholar 

Hosaka, T. et al. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology 58, 98–107 (2013).

Article  CAS  PubMed  Google Scholar 

Marcellin, P. et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 381, 468–475 (2013).

Article  CAS  PubMed  Google Scholar 

Yeo, Y. H. et al. Factors associated with rates of HBsAg seroclearance in adults with chronic HBV infection: a systematic review and meta-analysis. Gastroenterology 156, 635–646.e9 (2019).

Article  CAS  PubMed  Google Scholar 

Yip, T. C. et al. HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues. J. Hepatol. 70, 361–370 (2019).

Article  CAS  PubMed  Google Scholar 

Lim, S. G. et al. Switching to or add-on peginterferon in patients on nucleos(t)ide analogues for chronic hepatitis B: the SWAP RCT. Clin. Gastroenterol. Hepatol. 20, e228–e250 (2022).

Article  CAS  PubMed  Google Scholar 

Feld, J. J., Lok, A. S. & Zoulim, F. New perspectives on development of curative strategies for chronic hepatitis B. Clin. Gastroenterol. Hepatol. 21, 2040–2050 (2023).

Article  CAS  PubMed  Google Scholar 

Janssen, H. L. A. et al. Randomised phase 2 study (JADE) of the HBV capsid assembly modulator JNJ-56136379 with or without a nucleos(t)ide analogue in patients with chronic hepatitis B infection. Gut 72, 1385–1398 (2023).

Article  CAS  PubMed  Google Scholar 

Yuen, M. F. et al. Phase IIa, randomised, double-blind study of GSK3389404 in patients with chronic hepatitis B on stable nucleos(t)ide therapy. J. Hepatol. 77, 967–977 (2022).

Article  CAS  PubMed  Google Scholar 

Yuen, M. F. et al. Efficacy and safety of bepirovirsen in chronic hepatitis B infection. N. Engl. J. Med. 387, 1957–1968 (2022).

Article  CAS  PubMed  Google Scholar 

Chang, M. H. et al. Long-term effects of hepatitis B immunization of infants in preventing liver cancer. Gastroenterology 151, 472–480.e1 (2016).

Article  CAS  PubMed  Google Scholar 

Wong, G. L. et al. Universal HBV vaccination dramatically reduces the prevalence of HBV infection and incidence of hepatocellular carcinoma. Aliment. Pharmacol. Ther. 56, 869–877 (2022).

Article  CAS  PubMed  Google Scholar 

Di Lello, F. A., Martinez, A. P. & Flichman, D. M. Insights into induction of the immune response by the hepatitis B vaccine. World J. Gastroenterol. 28, 4249–4262 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar